drugset
drugset / Trial / NCT04902105

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

NCT04902105 ↗

Phase 1 Completed 38 enrolled Emalex Biosciences Inc. Nuventra, Inc. · collabSyneos Health · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is a single center, open-label, fixed sequence, drug-drug interaction (DDI) study in healthy subjects.

Timeline

Start
2021-05-13
Primary completion
2021-07-06
Completion
2021-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Divalproex Sodium Small molecule 1250 mg Oral
Subject Ecopipam Small molecule 200 mg Oral
Subject Mefenamic acid Small molecule 250 mg Oral

Indications

No indication recorded.